EQT Logo
Current Portfolio

Bespak

A globally leading contract developer and manufacturer focused on inhalation drug delivery products, operating as a partner to global pharma companies.

Established as a standalone company in 2024 following the carve-out of Recipharm’s former Advanced Delivery Systems business, Bespak operates three sites across the UK and the US.

Key Facts
Sector

Healthcare

Country

United Kingdom

Fund

EQT IX

Entry

2021

Responsible Advisor

Matthias Wittkowski

Website

Bespak

A person is handling a white cylindrical object in a manufacturing setting

About Bespak

Bespak is a global pharmaceutical contract development and manufacturing organization (CDMO) specializing in innovative inhaled and nasal drug delivery systems, including metered dose and dry powder inhalers, as well as nasal sprays.
The company leverages cutting-edge technology to enhance drug delivery efficiency and serves blue-chip pharma companies across Europe and the United States. In addition, Bespak is also viewed as a sustainability leader in the transition to greener inhaler solutions.

Market Trends and Drivers

Bespak operates in the attractive drug delivery product market, with strong growth outlook driven by increasing incidence, product innovation and growing outsourcing share to CDMOs.

The company holds a leading market position in pressurized metered dose inhaler valves and is well placed to drive and capitalize on the upcoming green propellant opportunity, which is being accelerated by regulatory pressures to phase out current CO2-heavy propellants.

Investment Potential

The carve out of Bespak as a standalone company is expected to unlock its full potential by driving product development and customer acquisition in its core business of pressurized metered dose inhaler valves and dry powder inhalers, as well as by winning new manufacturing contracts. Bespak’s ambition is to consolidate its footprint as E2E player with strong market position and technology at the forefront of the green propellant shift. Additionally, growth acceleration is expected to come from increased focus on high-growth niches in nasal spray devices and soft mist inhalers where Bespak has proprietary IP and is early to market.

Board of directors

Chairperson

Kåre Schultz

Board member

Matthias Wittkowski

Board member

Ulrich Faessler

Board member

Greg Behar

Board member

Anne Whitaker

Board member

Chris Hirst

Board member

Oren Klug

Management

CEO

Chris Hirst

CFO

Maria Neeve

Do You Want to Know More?

We are eager to explore how we can achieve great things together.